Moreover, alterations in cell cycle proteins, including the silencing of cyclin dependent kinase (CDK) inhibitor p16 and p15 are associated with resistance to EGFR TKI in NSCLC patients [66]. Here, EGFR is linked to non-small cell lung carcinoma.